2024-519194-19-00招募中2 期
A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Idp Discovery Pharma S.L.12 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2024年12月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 62
- 试验地点
- 12
- 主要终点
- Maximum tolerated dose (MTD): based on the incidence of DLTs observed at the end of Cycle 1 (28 days).
研究概览
简要总结
Dose-Escalation Phase (Phase 1): To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), B-cell lymphoma, and chronic lymphocytic leukemia (CLL).
Expansion Phase (Phase 2): To evaluate the overall response rate (ORR) in patients with MM, B-cell lymphoma or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 years
- •Performance status (ECOG) ≤ 2
- •Life expectancy ≥3 months
- •Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements.
- •Patient has given voluntary written informed consent before performance of any studyrelated procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to receive the available treatments.
- •Adequate hematological or biochemical parameters as specified below a. Hemoglobin > 8.0 g/dl (without transfusion support within 7 days) b. Platelets count > 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L. c. Absolute neutrophil count (ANC) > 0.75 x109/L (without G-CSF support within 7 days) d. Aspartate transaminase (AST): <2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) e. Alanine transaminase (ALT): < 2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) f. Total bilirubin: < 2 x the upper limit range. g. Calculated or measured creatinine clearance: >30 mL/min (calculated from the Cockcroft-Gault formula).
- •Left ventricular ejection fraction > 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.
排除标准
- •Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade <2 symptomatic peripheral neuropathy is allowed.
- •The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels <50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive).
- •Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle
- •Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
- •Limitation of the patient’s ability to comply with the treatment or follow-up protocol.
- •If a COVID-19 vaccine is administered, it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase”).
- •Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence).
- •History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site)
- •History of clinically significant hypotension.
- •History of clinically significant allergic or hyper-sensitivity reactions.
- •History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to): - Thromboembolism - Peripheral arterial disease - Vasculitis
- •Other relevant diseases or adverse clinical conditions: - Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study. - Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months). - History of significant neurological or psychiatric disorders
- •Clinically significant or active infection.
- •Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
结局指标
主要结局
Maximum tolerated dose (MTD): based on the incidence of DLTs observed at the end of Cycle 1 (28 days).
Maximum tolerated dose (MTD): based on the incidence of DLTs observed at the end of Cycle 1 (28 days).
Recommended phase 2 dose (RP2D): dose used in subsequent Expansion phase. The RP2D will be determined in discussion with the Investigators and the Sponsor based on safety (dose limiting toxicity), PK, PD, and any cumulative toxicity after multiple cycles.
Recommended phase 2 dose (RP2D): dose used in subsequent Expansion phase. The RP2D will be determined in discussion with the Investigators and the Sponsor based on safety (dose limiting toxicity), PK, PD, and any cumulative toxicity after multiple cycles.
Overall response rate (ORR) for CLL, MM and Lymphomas, respectively.
Overall response rate (ORR) for CLL, MM and Lymphomas, respectively.
次要结局
- Duration of response (DoR), defined as the time from documentation of disease response to disease progression.
- Time to progression (TTP), time from the first treatment day to objective disease progression; does not include deaths.
- Progression-free survival (PFS) defined as the interval between the first treatment day to the first sign of disease progression or death from any cause.
- Event-free survival (EFS) defined as the interval time between the first treatment day to disease progression, death, or discontinuation of treatment from any cause (e.g., toxicity, patient preference, or initiation of a new treatment without documented progression).
- Overall survival (OS) defined as the interval between the first treatment day to death from any cause.
- Safety endpoints: Vital signs, Physical examination, Hematology, Biochemistry, Urinalysis, Electrocardiograms (ECG), All grades AEs and SAEs
- Pharmacokinetics parameters: AUClast, Cmax, CL, Css, Ctrough, Ke, t1/2, Tmax, Vd
研究者
Clinical Operations Manager
Scientific
Idp Discovery Pharma S.L.
研究点 (12)
Loading locations...
相似试验
招募中
2 期
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)2025-521902-17-00Idp Discovery Pharma S.L.60
招募中
2 期
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer2022-502774-17-00AstraZeneca AB95
招募中
2 期
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors2023-507141-28-00Sanofi-Aventis Recherche & Developpement115
招募中
2 期
(Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with metastatic prostate cancer.Metastatic Prostate Cancer2024-520026-11-00AstraZeneca AB38
招募中
2 期
GEN1047 for Solid Tumors - First in Human (FIH) Trial2024-510722-10-00Genmab A/S268